Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2127399 Open Label Extension in Rheumatoid Arthritis
NCT00837811Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2009
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Feb 2009; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00837811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00837811.